Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $20.00 | Neutral | Analyst |
| 11/6/2024 | $22.00 → $19.00 | Buy → Neutral | BofA Securities |
| 10/11/2024 | $24.00 | Overweight | KeyBanc Capital Markets |
| 8/12/2024 | $22.00 | Buy | BofA Securities |
| 8/12/2024 | $18.00 | Buy | Loop Capital |
| 8/12/2024 | $24.00 | Overweight | Stephens |
| 8/12/2024 | $21.00 | Buy | Citigroup |
| 8/12/2024 | $23.00 | Outperform | RBC Capital Mkts |
Ardent Health Partners, Inc. (NYSE:ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that its board of directors voted to change the Company's name to Ardent Health, Inc., effective June 3, 2025. The updated name aligns the Company's legal name with its practice of referring to the organization as "Ardent Health" in its communications, ensuring a clear and consistent brand identity. The name change will have no impact on Ardent Health's trading symbol on the New York Stock Exchange, its CUSIP number, nor the rights of its stockholders. Ardent Health anticipates that its common stock will begin
Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Chris Schoeplein as chief development officer. In this new role, Schoeplein will lead development efforts across Ardent's existing markets and support the organization's expansion into new regions. He will be responsible for driving growth across inpatient and outpatient care settings through acquisitions, partnerships and joint ventures. Additionally, he will guide due diligence, market intelligence and integration planning to advance Ardent's long-term growth strategy. "We are excited to welcome Chris to Ardent at a pivotal time in our gr
Ardent Health Partners, Inc. (NYSE:ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced results for the quarter ended March 31, 2025. First Quarter 2025 Operating and Financial Summary All comparisons are versus the same prior year period. See the footnotes to the Operating Statistics table of this press release for definitions of the metrics below and a full list of key operating metrics. Total Revenue $1.50 billion 4.0% growth Y/Y Net Income Attributable to Ardent Health $41 million Adjusted EBITDA(1) $98 million 2.5% growth Y/Y Adjusted EBITDAR(1) $139 million